Boston, MA 04/07/2014 (wallstreetpr) – The leading healthcare company, Abbott Laboratories (NYSE:ABT), has invariably continued to contribute significantly to the global healthcare. By developing technologies and products that would see a tremendous change in the healthcare sector, this globally famous company has maintained its most crucial stand in improving people’s life worldwide.
An admirable approval for an ingenious creation
The international health care company had a great time in the recent past when it declared that it’s most amazing creation “Supera Peripheral Stent System” has received the much-desired approval from the U.S. Food and Drug Administration. Certainly, Abbott deserved this much awaited confirmation from the U.S. Food and Drug Administration (hereafter FDA) for its incessant hard work by its skilled professionals. Supera Peripheral Stent System will prove its value in curing the blocked blood vessels driven by peripheral artery disease. Such blockage is usually caused in the upper part of the leg.
Supera Stent is all set to create vital impact internationally. This drug has been proved to be a highly effective remedy for opening up of the blocked blood vessels. This latest product will strengthen Abbott’s portfolio even more. The Lab’s vascular collection possesses “drug eluting stents” like Absorb and Xience Xpedition.
Besides delivering a strong position in the market, the approval of the stent by the FDA has also given a boost to its sales. Last year, vascular business had generated Abbott Laboratories (NYSE:ABT) a turnover of $3 billion.
In addition, Abbott has more of such effectual products in store. The Lab is striving hard to improve and broaden its product portfolio. So, that assures a more promising future to this world’s leading life-improving company.
Reveal Financial Results
Abbott Laboratories (NYSE:ABT) is to announce the financial earning results of 1Q2014 on April 16, 2014 prior to the opening of the market. On this coming Wednesday, the public will get to know the total income that the company has earned in the last three months.
